SCHEMBL180845

SCHEMBL180845

[O]C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.71
TSHR P16473 2/20 0.71
CASP1 P29466 1/20 0.71
ALDH1A1 P00352 4/20 0.63
MAPK1 P28482 1/20 0.63
HIF1A Q16665 1/20 0.63
MAPT P10636 3/20 0.61
KDM4E B2RXH2 1/20 0.61
ERCC5 P28715 1/20 0.55
FEN1 P39748 1/20 0.55
SRD5A2 P31213 1/20 0.55
TP53 P04637 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
POLB P06746 3/20 0.52
THRB P10828 1/20 0.52
RECQL P46063 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
FLT1 P17948 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30185351 0.85 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL195020 0.85 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL8065539 0.85 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL5732135 0.83 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL5667181 0.83 ALDH1A1 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL107060 0.83 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL19998346 0.83 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL111279 0.83 TSHR (1.00) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL322161 0.81 TSHR (0.65) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL1303476 0.81 TSHR (0.95) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551360-B2 Pyrazoline-3,5-dione-containing compositions for dyeing keratin fibres; their use in dyeing as couplers; dyeing process VIDAL LAURENT (FR) 2003-04-22 US claimed
US-6340372-B1 Compositions for dyeing keratin fibers containing S-oxide-thiazolo-azoles and/or S,S-dioxide-thiazolo-azoles; their use for dyeing as couplers, method of dyeing L'OREAL S.A. (FR) 2002-01-22 US claimed
US-6139589-A HAIR DYES L'OREAL S.A. (FR) 2000-10-31 US claimed
US-6063136-A Compositions containing pyrrolo-oxazole couplers for dyeing keratin fibers and dyeing methods L'OREAL S.A. (FR) 2000-05-16 US claimed
US-5116990-A MAGENTA DYE-FORMING COUPLER FUJI PHOTO FILM CO., LTD. (JP) 1992-05-26 US claimed
EP-0170164-B1 SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL FUJI PHOTO FILM CO., LTD. (JP) 1988-10-05 EP claimed
EP-0249999-A2 Triazolyl ethyl ethers and fungicides containing them BASF Aktiengesellschaft (DE) 1987-12-23 EP claimed
US-H122-H PYRAZOLOAZOLE-TYPE MAGENTA COUPLER DISPERSED IN A HIGH-BOILING PHOSPHATE SOLVENT FUJI PHOTO FILM CO., LTD. (JP) 1986-09-02 US claimed
EP-0170164-A2 Silver halide color photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1986-02-05 EP claimed
US-20130210786-A1 TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS PHYTOPHARM PLC (GB) 2013-08-15 US disclosed
EP-2595621-A1 TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS Phytopharm PLC (GB) 2013-05-29 EP disclosed
EP-2479183-A2 Polymorphs of sarsasapogenin Phytopharm PLC (GB) 2012-07-25 EP disclosed
US-20120034193-A1 TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS PHYTOPHARM PLC (GB) 2012-02-09 US disclosed
WO-2012010896-A1 TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS PHYTOPHARM PLC (GB) 2012-01-26 WO disclosed
EP-0119860-A2 Pyrazolo magenta couplers used in silver halide photography FUJI PHOTO FILM CO., LTD. (JP) 1984-09-26 EP disclosed
EP-0087596-A1 Process for the preparation of 5-substituted 1-chloro-3,3-dimethyl-pentan-2-ones BAYER AG (DE) 1983-09-07 EP disclosed
US-4239851-A DISSOLVING AN OIL SOLUBLE ADDITIVE IN AN EPOXY COMPOUND FUJI PHOTO FILM CO., LTD. (JP) 1980-12-16 US disclosed
US-4101464-A Process for preparing foamed solids using two or more azo compounds PENNWALT CORPORATION (US) 1978-07-18 US disclosed
US-4029615-A AZO COMPOUNDS PENNWALT CORPORATION (US) 1977-06-14 US disclosed
US-3993609-A ACID SENSITIVE AZO PROMOTERS PENNWALT CORPORATION (US) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120034193-A1 TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS BDNF, NGF, GFRA1 SMN1; SMN2 80/4885TSHR 2367/4885CASP1 547/4885
US-20130210786-A1 TREATMENT OF L-DOPA, DOPAMINE AGONIST AND/OR DOPAMINE ENHANCER INDUCED DISORDERS SNCA, DBH, COMT SMN1; SMN2 1238/4885TSHR 1166/4885CASP1 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.